157 related articles for article (PubMed ID: 35383291)
1. Exploring the future of research in the Tp53 field.
Levine AJ
Cell Death Differ; 2022 May; 29(5):893-894. PubMed ID: 35383291
[No Abstract] [Full Text] [Related]
2. Exploring the Functions of Mutant p53 through
Romashin D; Rusanov A; Arzumanian V; Varshaver A; Poverennaya E; Vakhrushev I; Netrusov A; Luzgina N
Curr Issues Mol Biol; 2024 Feb; 46(2):1451-1466. PubMed ID: 38392212
[TBL] [Abstract][Full Text] [Related]
3. Gaining insights into relevance across cancers based on mutation features of TP53 gene.
Mei Y; Liang D; Wang T; Yu D
Biochem Biophys Rep; 2021 Dec; 28():101165. PubMed ID: 34786492
[TBL] [Abstract][Full Text] [Related]
4. Targeting mutant TP53 as a potential therapeutic strategy for the treatment of osteosarcoma.
Tang F; Min L; Seebacher NA; Li X; Zhou Y; Hornicek FJ; Wei Y; Tu C; Duan Z
J Orthop Res; 2019 Mar; 37(3):789-798. PubMed ID: 30667081
[TBL] [Abstract][Full Text] [Related]
5. Prevalence and functional consequence of TP53 mutations in pediatric adrenocortical carcinoma: a children's oncology group study.
Wasserman JD; Novokmet A; Eichler-Jonsson C; Ribeiro RC; Rodriguez-Galindo C; Zambetti GP; Malkin D
J Clin Oncol; 2015 Feb; 33(6):602-9. PubMed ID: 25584008
[TBL] [Abstract][Full Text] [Related]
6. ERIC recommendations on TP53 mutation analysis in chronic lymphocytic leukemia.
Pospisilova S; Gonzalez D; Malcikova J; Trbusek M; Rossi D; Kater AP; Cymbalista F; Eichhorst B; Hallek M; Döhner H; Hillmen P; van Oers M; Gribben J; Ghia P; Montserrat E; Stilgenbauer S; Zenz T;
Leukemia; 2012 Jul; 26(7):1458-61. PubMed ID: 22297721
[TBL] [Abstract][Full Text] [Related]
7. Meta-analysis of the prognostic impact of TP53 co-mutations in EGFR-mutant advanced non-small-cell lung cancer treated with tyrosine kinase inhibitors.
Ferrara MG; Belluomini L; Smimmo A; Sposito M; Avancini A; Giannarelli D; Milella M; Pilotto S; Bria E
Crit Rev Oncol Hematol; 2023 Apr; 184():103929. PubMed ID: 36773668
[TBL] [Abstract][Full Text] [Related]
8. Applications of the human p53 knock-in (Hupki) mouse model for human carcinogen testing.
Besaratinia A; Pfeifer GP
FASEB J; 2010 Aug; 24(8):2612-9. PubMed ID: 20371617
[TBL] [Abstract][Full Text] [Related]
9. Detection of TP53 gene mutation in blood of breast cancer patients based on circulating tumor DNA and its application in prognosis.
Lu Q; Wei L; Cai S; Zhang Z; Zhang L
Cell Mol Biol (Noisy-le-grand); 2023 Nov; 69(11):200-206. PubMed ID: 38015519
[TBL] [Abstract][Full Text] [Related]
10. Molecular characterization of squamous cell carcinoma of the anal canal.
Armstrong SA; Malley R; Wang H; Lenz HJ; Arguello D; El-Deiry WS; Xiu J; Gatalica Z; Hwang JJ; Philip PA; Shields AF; Marshall JL; Salem ME; Weinberg BA
J Gastrointest Oncol; 2021 Oct; 12(5):2423-2437. PubMed ID: 34790403
[TBL] [Abstract][Full Text] [Related]
11. Mutations in TP53 or DNA damage repair genes define poor prognostic subgroups in primary prostate cancer.
Nientiedt C; Budczies J; Endris V; Kirchner M; Schwab C; Jurcic C; Behnisch R; Hoveida S; Lantwin P; Kaczorowski A; Geisler C; Dieffenbacher S; Falkenbach F; Franke D; Görtz M; Heller M; Himmelsbach R; Pecqueux C; Rath M; Reimold P; Schütz V; Simunovic I; Walter E; Hofer L; Gasch C; Schönberg G; Pursche L; Hatiboglu G; Nyarangi-Dix J; Sültmann H; Zschäbitz S; Koerber SA; Jäger D; Debus J; Duensing A; Schirmacher P; Hohenfellner M; Stenzinger A; Duensing S
Urol Oncol; 2022 Jan; 40(1):8.e11-8.e18. PubMed ID: 34325986
[TBL] [Abstract][Full Text] [Related]
12.
Eskelund CW; Dahl C; Hansen JW; Westman M; Kolstad A; Pedersen LB; Montano-Almendras CP; Husby S; Freiburghaus C; Ek S; Pedersen A; Niemann C; Räty R; Brown P; Geisler CH; Andersen MK; Guldberg P; Jerkeman M; Grønbæk K
Blood; 2017 Oct; 130(17):1903-1910. PubMed ID: 28819011
[TBL] [Abstract][Full Text] [Related]
13. Potential impact of (rs 4645878) BAX promoter -248G>A and (rs 1042522) TP53 72Arg>pro polymorphisms on epithelial ovarian cancer patients.
Dholariya S; Mir R; Zuberi M; Yadav P; Gandhi G; Khurana N; Saxena A; Ray PC
Clin Transl Oncol; 2016 Jan; 18(1):73-81. PubMed ID: 26209050
[TBL] [Abstract][Full Text] [Related]
14.
Molica M; Mazzone C; Niscola P; de Fabritiis P
Front Oncol; 2020; 10():610820. PubMed ID: 33628731
[No Abstract] [Full Text] [Related]
15. In search of TP53 mutational hot spots for Li-Fraumeni syndrome in Asian populations.
Lo Piccolo L; Jantrapirom S; Moonmuang S; Teeyakasem P; Pasena A; Suksakit P; Charoenkwan P; Pruksakorn D; Koonrungsesomboon N
Trop Med Int Health; 2021 Nov; 26(11):1401-1410. PubMed ID: 34478609
[TBL] [Abstract][Full Text] [Related]
16.
Shin DY
Cancers (Basel); 2023 Sep; 15(19):. PubMed ID: 37835510
[TBL] [Abstract][Full Text] [Related]
17. Quantitative Analysis of TP53-Related Lung Cancer Based on Radiomics.
Qiao H; Ding Z; Zhu Y; Wei Y; Xiao B; Zhao Y; Feng Q
Int J Gen Med; 2022; 15():8481-8489. PubMed ID: 36510487
[TBL] [Abstract][Full Text] [Related]
18.
Ball S; Loghavi S; Zeidan AM
Leuk Lymphoma; 2023 Mar; 64(3):540-550. PubMed ID: 36323304
[TBL] [Abstract][Full Text] [Related]
19. Integrative Analysis of the Role of
Liu T; Du J; Cheng X; Wei J
Curr Issues Mol Biol; 2023 Nov; 45(12):9606-9633. PubMed ID: 38132447
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of TP53 mutations with the AmpliChip p53 research test in chronic lymphocytic leukemia: correlation with clinical outcome and gene expression profiling.
Chiaretti S; Tavolaro S; Marinelli M; Messina M; Del Giudice I; Mauro FR; Santangelo S; Piciocchi A; Peragine N; Truong S; Patten N; Ghia EM; Torrente I; De Propris MS; Nanni M; Lawrence J; Guarini A; Foà R
Genes Chromosomes Cancer; 2011 Apr; 50(4):263-74. PubMed ID: 21319261
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
